Oncosec Medical (ONCS) Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020
November 9, 2020 8:36 AM ESTPENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients.
TAVO + KEYTRUDA led to a 30% ORR in the first 54 out of 100 planned patients. This interim investigator assessed ORR is much higher than the primary efficacy endpoint for the study, which is a 20% ORR determined by blinded... More
